KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Current Deferred Revenue (2016)

Gilead Sciences filings provide 8 years of Current Deferred Revenue readings, the most recent being $202.0 million for Q4 2016.

  • On a quarterly basis, Current Deferred Revenue fell 54.09% to $202.0 million in Q4 2016 year-over-year; TTM through Dec 2016 was $202.0 million, a 54.09% decrease, with the full-year FY2016 number at $202.0 million, down 54.09% from a year prior.
  • Current Deferred Revenue hit $202.0 million in Q4 2016 for Gilead Sciences, down from $361.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $529.0 million in Q1 2016 to a low of $93.7 million in Q2 2012.
  • Median Current Deferred Revenue over the past 5 years was $126.8 million (2013), compared with a mean of $214.2 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 296.72% in 2015 and later tumbled 54.09% in 2016.
  • Gilead Sciences' Current Deferred Revenue stood at $103.2 million in 2012, then rose by 7.6% to $111.0 million in 2013, then grew by 20.72% to $134.0 million in 2014, then skyrocketed by 228.36% to $440.0 million in 2015, then tumbled by 54.09% to $202.0 million in 2016.
  • The last three reported values for Current Deferred Revenue were $202.0 million (Q4 2016), $361.0 million (Q3 2016), and $345.0 million (Q2 2016) per Business Quant data.